TSVT Stock Discussion
2seventy bio, Inc. Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc. operates independently of bluebird bio, Inc. as of November 4, 2021.
Industry: Biotechnology
Keywords: Medicine Cancer Life Sciences Gene Therapy Multiple Myeloma Breakthrough Therapy Chimeric Antigen Receptor T Cell
Recent Comments
- TraderMike on Market Recap for Friday, March 8, 2024
- Don_Marat on Market Recap for Friday, March 8, 2024
- TraderMike on Trades of the Week: Feb 12 - Feb 16, 2024
- Cos3 on Trades of the Week: Feb 12 - Feb 16, 2024
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
From the Blog
Popular Now
Featured Articles